基于人工智能和液相相干光断层扫描引导下对使用替巴尼布林治疗的光化性角化病的随访1 - Suppr

Suppr

超能文献

AI-based and LC-OCT-guided follow-up of actinic keratoses under treatment with tirbanibulin 1.

作者信息

Thamm Janis Raphael, Welzel Julia, Schuh Sandra

机构信息

Department of Dermatology and Allergology, University Hospital Augsburg, Augsburg, Germany.

出版信息

J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e35-e38. doi: 10.1111/jdv.20059. Epub 2024 May 4.

DOI:10.1111/jdv.20059

PMID:38702995

Abstract

摘要

相似文献

AI-based and LC-OCT-guided follow-up of actinic keratoses under treatment with tirbanibulin 1.基于人工智能和液相相干光断层扫描引导下对使用替巴尼布林治疗的光化性角化病的随访1

J Eur Acad Dermatol Venereol. 2025 Jan;39(1):e35-e38. doi: 10.1111/jdv.20059. Epub 2024 May 4.

[Tirbanibulin in the treatment of actinic keratoses: description of a case with instrumental evaluation and long-term follow-up.].[替拉替尼治疗光化性角化病：1例病例的器械评估及长期随访描述。]

Recenti Prog Med. 2024 Oct;115(10):37e-41e. doi: 10.1701/4357.43475.

1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses.1%替比嘧啶软膏治疗光化性角化病。

Ann Pharmacother. 2022 Apr;56(4):494-500. doi: 10.1177/10600280211031329. Epub 2021 Jul 23.

Artificial intelligence-based PRO score assessment in actinic keratoses from LC-OCT imaging using Convolutional Neural Networks.基于卷积神经网络的液相色谱-光学相干断层扫描成像对光化性角化病进行基于人工智能的PRO评分评估。

J Dtsch Dermatol Ges. 2023 Nov;21(11):1359-1366. doi: 10.1111/ddg.15194. Epub 2023 Sep 14.

Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.三期临床试验研究替比嘧啶软膏治疗光化性角化病。

N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040.

Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022.替比嘧啶 1%软膏在光化性角化病中的疗效和安全性：来自两项 III 期临床试验和在 2022 年欧洲皮肤病学和性病学会大会上展示的真实临床实践的数据。

J Eur Acad Dermatol Venereol. 2024 Jan;38 Suppl 1:3-15. doi: 10.1111/jdv.19636.

Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses.1%替拉替尼软膏疗效、安全性及治疗满意度的初步证据：光化性角化病的临床视角

Pharmaceuticals (Basel). 2023 Dec 4;16(12):1686. doi: 10.3390/ph16121686.

Response Rate to the Intervention with Tirbanibulin 1% Ointment for Treating Actinic Keratoses in People Living with HIV Infection.1%替拉替尼软膏干预治疗HIV感染者光化性角化病的缓解率

Diagnostics (Basel). 2025 Feb 7;15(4):401. doi: 10.3390/diagnostics15040401.

Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients.替比嘧啶 1%软膏治疗癌前病变的疗效和耐受性：250 例意大利真实世界多中心观察研究。

Int J Dermatol. 2024 Nov;63(11):1566-1574. doi: 10.1111/ijd.17168. Epub 2024 Apr 11.

Tirbanibulin: A New Topical Therapy for Actinic Keratoses With a Novel Mechanism of Action and Improved Ease of Use.替拉替林：一种用于光化性角化病的新型局部治疗药物，具有全新作用机制且使用便利性得到改善。

Clin Pharmacol Drug Dev. 2021 Oct;10(10):1126-1129. doi: 10.1002/cpdd.1024.

引用本文的文献

An Assessment of Cellular Atypia Utilizing Line-Field Confocal Optical Coherence Tomography (LC-OCT).利用线场共聚焦光学相干断层扫描（LC-OCT）评估细胞异型性

Skin Res Technol. 2025 Sep;31(9):e70227. doi: 10.1111/srt.70227.

Clinical and Dermoscopic Diagnosis of Actinic Keratosis.光化性角化病的临床与皮肤镜诊断

Dermatol Pract Concept. 2024 Jul 1;14(3 S1):e2024147S. doi: 10.5826/dpc.1403S1a147S.

Epidemiology and Risk Factors of Actinic Keratosis. What is New for The Management for Sun-Damaged Skin.光化性角化病的流行病学与危险因素。日光损伤皮肤管理的新进展。

Dermatol Pract Concept. 2024 Sep 1;14(3 S1):e2024146S. doi: 10.5826/dpc.1403S1a146S.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验